HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Opioid-Withdrawal Beverage Seller Latest Target Of FDA-FTC Joint Enforcement

This article was originally published in The Rose Sheet

Executive Summary

While essentially all products labeled as dietary supplements but marketed with claims to treat diseases or illnesses could be targets of FTC enforcement against unsubstantiated advertising, FDA warnings to firms linked to those products generally don't discuss violations of FTC rules. But the warning to Up-Inya Beverages, like firms previously identified as making opioid-withdrawal claims, included an explanation of how it's in FTC's crosshairs, too.

You may also be interested in...



Opioid Drug Sales Online Draw US FDA Warnings, Prompt Summit Meeting

At June 27 "Online Opioid Summit," FDA officials, pharma sales researchers, and industry stakeholders will discuss collaborating for stronger impact against the opioid crisis by reducing the availability of illicit products online."The internet is virtually awash in illegal narcotics and we’re going to be taking new steps to work with legitimate internet firms to voluntarily crack down on these sales," says Commissioner Scott Gottlieb.

Drug Abuse Withdrawal Supplement Marketers Warned, Claims And Sales Continue

FDA and FTC send joint warning letters to 11 US firms about 12 products marketed as unapproved drugs with claims about aiding in the treatment of opioid addiction and withdrawal. FDA also thanks CSPI for suggesting the agencies investigate a scourge of fraudulent drug-abuse withdrawal claims.

Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation

Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS121712

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel